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Abstract 
Purpose: To investigate Heliotropium strigosum whole plant extract for its potential to reduce the blood 
glucose level of alloxan-induced diabetic mice. 
Methods: Preliminary phytochemical analysis was carried out using standard procedures. Diabetes was 
induced in Balb/c mice by injecting alloxan (200 mg/kg i.p.). The crude methanol extract of Heliotropium 
strigosum (Hs.Cr, 30, 100 and 300 mg/kg doses) was administered daily to alloxan-induced diabetic 
mice for 15 days and its effect on fasting blood glucose levels, body weight and oral glucose tolerance 
was evaluated. Two control groups (non-diabetic control and diabetic control) received normal saline 
(0.2 ml). Metformin (500 mg/kg) was used as reference standard. 
Results: Heliotropium strigosum showed positive for the presence of alkaloids, tannins and flavonoids. 
The extract (30, 100 and 300 mg/kg) caused significant reduction in the fasting blood glucose level of 
alloxan-induced diabetic mice on days 5, 10 and 15 compared to diabetic control (p < 0.001). In this 
regard, the anti-hyperglycemic effect compared to the reference (metformin). The extract also time-
dependently decreased the body weight of the treated animals as well as improved tolerance of the oral 
glucose overload.  
Conclusion: These results indicate that Heliotropium strigosum possesses anti-hyperglycemic effect, 
reduces body weight and enhances the tolerance of glucose overload in mice. Further studies are 
therefore required to determine its feasiilty as an alternate herbal medicine in the management of 
diabetes in humans.  
 
Keywords: Heliotropium strigosum, Anti-hyperglycemic, Alloxan-induced diabetic mice, Blood glucose, 
Oral glucose tolerance, Body weight 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Diabetes mellitus is a metabolic disorder that 
tends to cause hyperglycemia due to inefficient 
working of the beta cells or resistance towards 
the insulin at the target tissues [1]. Diabetes 
causes microvascular and macrovascular 
complications. These include retinopathy, 
nephropathy, cardiovascular and cerebrovas-
cular diseases. Until 2013 382 million people had 
been suffering from diabetes and it is expected 
that the numbers may increase to 592 million by 
2035 [2]. Oral anti-diabetics with variant 
mechanisms along with injectable insulin and 
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insulin preparations are currently in use [3]. 
World Health Organization has permitted the use 
of plants with medicinal values as an alternate 
therapy [4]. According to estimation by Alarcon et 
al [5], only 350 species of plants have been 
scientifically validated out of 800 species with 
expected anti-diabetic potential. 
 
Heliotropium strigosum (known as ‘bhangra’ and 
‘kharsan’ in Pakistan) belongs to the family 
Boraginaecae. It has been used in the traditional 
system of medicine for the treatment of GI 
ailments, bites, boils, eyesores, ulcers and 
imbalance hormonal functions [6]. Anti-microbial, 
anti-oxidant [7], anti-inflammatory, analgesic, 
anticonvulsant [8], cytotoxic, phototoxic [9], 
spasmolytic, bronchodilator and vaso-relaxant 
actions of Heliotropium strigosum have been 
reported [10]. It contains strigosine as major 
alkaloid [11] and a trypsin inhibitor, phthalic acid 
ester, has also been isolated. The aerial parts of 
Heliotropium strigosum obtained from Punjab 
Province has been investigated for anti-diabetic 
activity on rats [12].  
 
In present study, the objective was to investigate 
the whole plant as an antihyperglycemic agent in 




Plant material and extraction 
 
The whole plant of Heliotropium strigosum was 
collected from Malakand Agency, Pakistan. Dr. 
Zafar Iqbal of Kohat University of Science and 
Technology, KPK, Pakistan authenticated it, and 
a voucher specimen (no. 1230-B) was deposited 
in herbarium at the same department. The plant 
material was kept in shade at room temperature 
for drying. The coarse powder was obtained by 
grinding the shade-dried whole plant at room 
temperature. Obtained powder was kept for 
maceration in 70 % methanol for 7 days with 
regular shaking and mixing at intervals [10]. The 
resultant methanol extract was concentrated on 
rotary evaporator under reduced pressure to 





All chemicals used in this study were of highest 
analytical grade. Metformin hydrochloride was 
obtained as a gift from Caraway 
Pharmaceuticals, Rawat, Islamabad. However, 
Alloxan monohydrate (inducing agent) and 
methanol (maceration) were purchased from 




In this study Balb-C mice (25 - 30 g) were used. 
Mice were housed at the Animal House of Riphah 
Institute of Pharmaceutical Sciences, where room 
temperature was maintained at 23 - 25  C . Mice 
were fed with standard diet and tap water. The 
rules for experimental use of animals complied 
with guidelines provided by “Principles of 
Laboratory Animal care” (NIH publication 85-23, 
revised 1985) [13]. Ethical approval was obtained 
prior to experimentation from Ethical Committee 
of Riphah Institute of Pharmaceutical Sciences, 
Riphah International University (ref no. 
REC/RIPS/2015/002).  
 
Preliminary phytochemical screening 
 
Hs.Cr was analysed for presence of phyto-
constituents like alkaloids, tannins, proteins, 
steroids and flavonoids through preliminary 
phytochemical analysis according to standard 
procedures [14]. Alkaloids were detected by using 
Dragendorff’s and Mayer’s reagent. Flavonoids 
tested using sodium hydroxide test. Tannins were 
detected using lead acetate test. Ninhydrin was 
used for protein detection. Steroids were tested 
using chloroform test. 
 
Assessment of blood glucose level and body 
weight  
 
Mice were acclimatized to lab conditions.  Mice 
were pre-fasted for 12 h and injected with freshly 
prepared solution of alloxan (200 mg/kg) intra-
peritoneal for induction of diabetes [15]. After 48 
h of alloxan induction mice with fasting blood 
glucose levels above 200 mg/dL along with signs 
of polyuria and polydipsia were considered 
diabetic and included in the study. Selected mice 
were divided into 5 groups (n=5). Group I (non-
diabetic mice normal control given saline), Group 
II (diabetic control mice) diabetic mice served 
saline, Group III, IV and V include diabetic mice 
that received 30, 100 and 300 mg/kg doses of 
Hs.Cr respectively. Group VI comprised of 
diabetic mice receiving standard drug metformin 
(500 mg/kg). All groups were treated respectively 
for 15 consecutive days. EASYGLUCO Auto-
coding Glucometer and weighing balance were 
used for monitoring blood glucose levels and 
body weight (g) at regular intervals. 
 
Oral glucose tolerance test  
 
The selected mice were kept on fasting for 14-15 
h and divided in non-diabetic control group, 
diabetic control group, test and standard drug 
treatment groups. The diabetic and non-diabetic 
control groups were administrated saline, test 
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group was given Hs.Cr (300 mg/kg) and standard 
group received metformin (500 mg/kg) 30 min 
prior to administration of oral D-glucose (2 g/Kg). 
Blood was withdrawn at 0 min (before glucose 
load), then at 30, 60, 90 and 120 min after 
glucose administration for assessment of blood 
glucose level using tail-prick method [16]. 
 
Acute toxicity test 
 
The oral toxicity test with acute doses was 
performed [17]. The overnight fasting mice (n = 
6) in each group were treated with Hs.Cr orally at 
acute doses of 1, 3 and 5 g/ Kg. Mice were 
observed for 48 h and any signs of Gi discomfort, 
diarrheal spots, discomfort, neurological/ 





The results are expressed as mean ± standard 
error of mean (SEM, n = 5). One-way analysis of 
variance (ANOVA) followed by Tukey post-hoc 
test is used as statistical parameter. P < 0.05 
was set as significantly different, and GraphPad 
program (GraphPad, San Diego, CA, USA) was 







Hs.Cr tested positive for the presence of 
alkaloids, tannins and flavonoids.  
 
Effect of Hs.Cr on blood glucose level 
 
Hs.Cr at doses of 30, 100 and 300 mg/kg 
significantly reduced the blood glucose of 
alloxan-induced diabetic mice (Figure 1), similar 
to what was seen in the metformin group. The 
animals of non-diabetic normal control group had 
fasting blood glucose levels of 109.4 ± 4.1 mg/dl 
at day 15 whereas that of diabetic control group 
was 225.6 ± 5.6 mg/dl. The group treated with 
Hs.Cr (30 mg/kg) showed significant reduction of 
blood glucose levels of 107.6 ± 2.4 mg/dl (***p < 
0.001 vs. diabetic control group) at day 15. At 
day 15 the dose of of Hs.Cr (100 mg/kg) 
significantly reduced blood glucose levels to 
103.2 ± 1.4 mg/dl (***p < 0.001 vs. diabetic control 
group). The blood glucose levels of Hs.Cr (300 
mg/Kg) showed a remarkable significant 
reduction to 98 ± 1.7 mg/dl (***p < 0.001 vs. 
diabetic control group) which is even better than 
metformin (500 mg/Kg) treated group that 
reduced blood glucose levels to 103 ± 3.9 mg/dl 
(***p < 0.001 vs. diabetic control group) at day 15. 
 
 
Figure 1: Bar-graph representing the blood glucose levels at different treatment days. Data is represented as 
mean ± SEM (n = 5); ***p < 0. 001 was obtained by comparison of the blood glucose values of treated groups to 
that of diabetic control group, one-way ANOVA followed by Tukey’s test 
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Table 1: Effect of Heliotropium strigosum crude extract (Hs.Cr) and metformin on the body weight of alloxan-
treated diabetic mice 
 
Treatment  Day 1 Day 5 Day 10 Day 15 
Non-diabetic control (saline 0.2 ml) 32.60 ± 0.6 32.46 ± 0.7 31.70 ± 0.8 32.21 ± 1.5 
Diabetic control (200 mg/kg) + (saline 0.2ml) 28.92 ± 1.6 28.22± 1.7 27.44 ± 1.6 27.40 ± 1.6 
Alloxan (200 mg/kg) + Hs.Cr (30 mg/kg) 21.2± 0.6 20.8 ± 0.7 19.9 ± 0.3 19.5 ± 0.4 
Alloxan (200 mg/kg) + Hs.Cr (100 mg/kg) 36.7 ± 1.7 35.6 ± 1.9 33.8 ± 1.7 33.1 ± 1.7 
Alloxan (200 mg/kg) + Hs.Cr (300 mg/kg) 35.3 ± 1.4 33.6 ± 1.7 30.3 ± 1.1 29.9 ± 1.1 
Alloxan (200 mg/kg) + Metformin (500  mg/kg) 24.6 ± 1.8 24.2 ± 1.7 23.7 ± 1.8 23.2 ± 1.8 
Values are mean ± SEM (n = 5) 
 
 
Figure 2: Bar-graph representing the blood glucose levels before and after administration of oral glucose load in 
mice. Data represented as mean ± SEM (n = 5); ***p < 0. 001 is obtained with Hs.Cr and metformin treated 
groups vs. alloxan-induced diabetic control group. one-way ANOVA followed by Tukey’s test 
 
Effect of Hs.Cr on body weight  
 
Hs.Cr at doses of 30, 100 and 300 mg/kg 
significantly reduced body weight of treated 
animals at days 5, 10 and 15th, compared to the 
initial body weights of each group. These effects 
of weight reduction were similar to that of 
metformin group (Table 1). 
 
Effect of Hs.Cr on glucose tolerance 
 
Hs.Cr at dose of 300 mg/kg significantly 
improved the tolerance of orally administered 
glucose (***p < 0.001 vs. diabetic control group), 
similar to that caused by metformin. After 
glucose (2 g/kg) overload, blood glucose levels 
of non-diabetic, diabetic, Hs.Cr (300 mg/kg) and 
metformin (500 mg/kg) treated group were 
recorded to be 115.6 ± 3.3 mg/dL, 336.8 ± 21.5 
mg/dL, 122.8 ± 3.7 mg/dL (***p < 0.001 vs. 
diabetic control group) and 114.6 ± 3.9 mg/dL 
(***p < 0.001 vs. diabetic control group) 
respectively at 120 mins (Figure 2). 
Acute toxicity 
 
Hs.Cr was safe even at doses as high as 3 g/kg. 
However, death was observed only at the dose 




In the present study, anti-diabetic potential of 
Heliotropium strigosum against alloxan-induced 
diabetes in mice was investigated. Alloxan is 
used as a toxic agent for induction of diabetes. It 
causes diabetes by destruction of pancreatic 
beta cells through necrosis due to oxidative 
stress induced by formation of reactive oxygen 
species. This leads to inhibition of insulin 
secretion resulting in persistent hyperglycemia or 
diabetes [18]. Heliotropium strigosum caused 
significant decrease in blood glucose levels of 
mice in dose-dependent and time-dependent 
fashion when compared to alloxan-treated 
diabetic group and standard group treated with 
metformin. Metformin is a biguanide oral anti-
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diabetic drug in market which is used as a 
standard drug [19].  
 
Metformin lowers the glucose levels by acting 
through numerous paths. This includes reducing 
hepatic glucose production, limiting glucose 
absorption in intestine and improving glucose 
uptake and utilization through enhancing insulin 
sensitivity [20]. In same pattern of metformin the 
plant extract also caused reduction in body 
weights of test mice measured at regular day 
intervals. Diabetes is often associated with 
obesity and it is known to be one of the major 
risk factors for diabetes, hence a drug with dual 
benefits of glycemic and weight control is of 
interest in diabetes associated with obesity. 
Hence it is a positive outcome of Heliotropium 
strigosum usage. Metformin also possess both 
weight reduction and anti-hyperlipidemic 
properties and hence is a drug of choice in 
diabetes associated with obesity [21]. In glucose-
loaded hyperglycemia model, which tends to 
assess oral glucose tolerance, Hs.Cr displayed 
considerably better tolerance of glucose overload 
in experimental intervals as does the metformin 
group. Excess of glucose in blood impels insulin 
secretion. The resultant insulin stimulates 
glucose uptake and use peripherally and controls 
processing of glucose through numerous 
mechanisms [17]. Hs.Cr produced lowering of 
blood glucose, body weight and enhanced 
glucose overload tolerance in a similar pattern to 
that of metformin, suggesting that Heliotropium 
strigosum may also have possibly mediated anti-
diabetic effect through aforementioned 
mechanism(s) of actions exerted by metformin. 
Qayyum et al [22] reported amylase inhibitory 
potential of Heliotropium strigosum. However, 
further advance molecular studies need to be 
conducted for elucidation of underlying 
pharmacodynamics involved. The anti-diabetic 
effect of Heliotropium strigosum observed may 
be due to the effect of rich phyto-constituents as 
alkaloids and flavonoids that possess 
hypoglycemic potential and are considered 
useful for treating diabetes as well us to reduce 
complication associated with it [23]. Major 
diseases occur due to the excessive oxidative 
stress induced by cellular injury [24]. Hs.Cr has 
been validated to possess antioxidant activity 
that makes it beneficial in reducing oxidative 
stress, which may be one of the prospected 




Heliotropium strigosum shows anti-
hyperglycemic effect in alloxan-induced diabetic 
mice and improves acute glucose tolerance. 
Thus, these findings study provide scientific 
justification of Heliotropium strigosum in the 
management of diabetes mellitus in traditional 
medicine system of Pakistan. Further studies will 
be carried out in future to identify the active anti-
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